Spots Global Cancer Trial Database for momelotinib
Every month we try and update this database with for momelotinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | NCT01236638 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia | NCT01998828 | Polycythemia Ve... Essential Throm... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis | NCT01969838 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib Ruxolitinib Placebo to matc... Placebo to matc... | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | NCT01236638 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) | NCT04173494 | Primary Myelofi... Post-polycythem... Post-essential ... | Momelotinib Placebo to matc... Danazol Placebo to matc... | 18 Years - | Sierra Oncology LLC - a GSK company | |
| A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | NCT06235801 | Myeloid Leukemi... | Gilteritinib Momelotinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | NCT06235801 | Myeloid Leukemi... | Gilteritinib Momelotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | NCT02101021 | Metastatic Panc... | Momelotinib Placebo to matc... Nab-paclitaxel Gemcitabine | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis | NCT01969838 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib Ruxolitinib Placebo to matc... Placebo to matc... | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis | NCT01423058 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | NCT01236638 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis | NCT01969838 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib Ruxolitinib Placebo to matc... Placebo to matc... | 18 Years - | Sierra Oncology LLC - a GSK company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
